engleski

Osteoprotegerin and bone markers in postmenopausal women

The role of osteoprotegerin, an inhibitor of osteoclast differentiation and activation, in the postmenopausal osteoporosis is still not clarified. Association of osteoprotegerin and standard bone markers was investigated in 123 postmenopausal women. Fifteen patients received antiresorptive therapy for osteoporosis. The following parameters associated with bone metabolism were measured in serum by standard methods or commercial kits: total and bone alkaline phosphatase, telopeptide (Crosslaps serum, Osteometer), osteoprotegerin and RANKL (both Biomedica). Standard biochemical parameters were increased in less than 5% of patients. Telopeptide was lower (p=0.02) in patients receiving antiresorptive therapy and also in those with menopause longer than 10 years. Relationships of both telopeptide (p=0.0005) and osteoprotegerin (p=0.02) were positive with menopause duration by second-degree equation. Osteoprotegerin correlated positively also with age (p=0.0005), total (p=0.008) and bone alkaline phosphatase (p=0.01). No significant correlation was found between osteoprotegerin and telopeptide, and none with RANKL. These results indicate that bone turnover was higher in patients within the first 10 postmenopausal years and in those not receiving antiresorptive therapy. The observed relationships of osteoprotegerin, bone markers, age and duration of menopause suggest that higher bone turnover rate was associated with higher osteoprotegerin concentrations. Similar findings were reported by other investigators and interpreted as compensatory osteoprotegerin synthesis during postmenopausal bone loss. Clinical significance of osteoprotegerin and RANKL was not confirmed.

osteoprotegerin; postmenopausal osteoporosis

nije evidentirano